文献速递MDS 与骨髓增殖性肿瘤

基于临床与基因组特征的骨髓增生异常综合征分类与个体化预后评估

Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes.
PubMed 文献 · J Clin Oncol · 2021-02-04

该研究回顾性纳入2043例MDS患者,整合47个基因突变与细胞遗传学异常,识别出8个基因组亚组,并构建整合63个临床与基因组变量的新型预后模型。模型在内部交叉验证和318例独立外部队列中预测生存与实际观察相关性良好,预测准确性优于现有工具。

要点

  • 基于基因组特征可将MDS分为8个亚组,各亚组预后不同。
  • SF3B1突变组生存较好,复杂核型/TP53异常及类急性白血病突变组预后最差。
  • 整合63个变量的新型预后模型可生成个体化生存预测,并已建立网页预测门户。

核心结论

  • MDS基因组景观揭示与特定临床特征和演化模式相关的不同亚组,为下一代疾病分类和预后提供概念验证。

研究设计与样本

  • 回顾性纳入2043例MDS患者,使用贝叶斯网络和Dirichlet过程整合47个基因突变与细胞遗传学异常。
  • 采用随机效应Cox比例风险多状态模型开发预后模型,并在318例独立病例中进行外部验证。

主要发现

  • 识别出8个MDS基因组亚组,其中5个亚组以剪接基因突变(SF3B1、SRSF2、U2AF1)为主导基因组特征。
  • SF3B1突变组与较好生存相关,特定共突变模式解释SF3B1和SRSF2相关MDS的临床异质性。
  • 复杂核型和/或TP53基因异常以及类急性白血病突变的MDS预后最差。
  • 5q缺失MDS根据突变基因数量和/或TP53突变状态聚为两个不同亚组。
  • 整合63个临床和基因组变量的新型预后模型在内部交叉验证和独立外部队列中预测与观察结局相关性良好,预测准确性显著优于现有预后工具。

关键数值与推荐

  • 共识别8个MDS基因组亚组。
  • 预后模型整合63个临床和基因组变量。
  • 外部验证队列包含318例病例。

临床怎么用

  • 可基于患者临床与基因组特征使用新型预后模型生成个体化生存预测。
  • 已创建网页门户,允许用户根据自定义的基因组和临床特征组合生成结局预测。

局限性

  • 研究为回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Recurrently mutated genes and chromosomal abnormalities have been identified in myelodysplastic syndromes (MDS). We aim to integrate these genomic features into disease classification and prognostication. METHODS: We retrospectively enrolled 2,043 patients. Using Bayesian networks and Dirichlet processes, we combined mutations in 47 genes with cytogenetic abnormalities to identify genetic associations and subgroups. Random-effects Cox proportional hazards multistate modeling was used for developing prognostic models. An independent validation on 318 cases was performed. RESULTS: We identify eight MDS groups (clusters) according to specific genomic features. In five groups, dominant genomic features include splicing gene mutations (SF3B1, SRSF2, and U2AF1) that occur early in disease history, determine specific phenotypes, and drive disease evolution. These groups display different prognosis (groups with SF3B1 mutations being associated with better survival). Specific co-mutation patterns account for clinical heterogeneity within SF3B1- and SRSF2-related MDS. MDS with complex karyotype and/or TP53 gene abnormalities and MDS with acute leukemia-like mutations show poorest prognosis. MDS with 5q deletion are clustered into two distinct groups according to the number of mutated genes and/or presence of TP53 mutations. By integrating 63 clinical and genomic variables, we define a novel prognostic model that generates personally tailored predictions of survival. The predicted and observed outcomes correlate well in internal cross-validation and in an independent external cohort. This model substantially improves predictive accuracy of currently available prognostic tools. We have created a Web portal that allows outcome predictions to be generated for user-defined constellations of genomic and clinical features. CONCLUSION: Genomic landscape in MDS reveals distinct subgroups associated with specific clinical features and discrete patterns of evolution, providing a proof of concept for next-generation disease classification and prognosis.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bersanelli M, Travaglino E, Meggendorfer M, et al. Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. J Clin Oncol. 2021. PMID: 33539200. doi:10.1200/JCO.20.01659

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。